Sinopep is a market-oriented and innovation-driven biopharmaceutical company. The company is focusing on the R&D, manufacturing and sales of pharmaceutical products both for peptide and small molecule. Through technological innovation, Sinopep is committed to solving technical bottlenecks in research and production, optimizing manufacturing process, building a whole product chain covering advanced intermediates, drug substances and drug products, so as to provide high-quality, green and cost-efficient products and services for the global pharmaceutical markets.
Sinopep pays great attention to research and innovation. Though more than 11 years, the company has successfully developed five technology platforms. They are: large scale solid-solution phase hybrid production technology, chiral-drug design and selection technology, continuous-flow microchannel green-chemistry technology, drug delivering technology, new peptide drug design technology.
Sinopep also mastered a series of core technologies which are very high level and high entry barriers. Up to today, the company has obtained 53 patents for various inventions, which are widely used in the research, development and production for the company's products.
Sinopep produces a wide range of products covering high demanding indications, such as diabetes, cardiovascular, oncology, antiviral, assisted fertility. Key products are liraglutide, semaglutide, thymalfasin, eptifibatide, bivalirudin, octreotide acetate, lanreotide acetate, cetrorelix, fulvestrant, oseltamivir. US DMF are available and most of them are active for reference in the above mentioned products.
The plant has been approved and inspected for GMP operation from Chinese authority and has been inspected by US FDA three times in 2014, 2016, 2019.